Therapeutics News

AbbVie announced that the FDA has approved Skyrizi, an interleukin-23 inhibitor for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Initial phase 2 data show improvement in Bullous Pemphigoid Disease Area Index and blister score for the first of three patients treated with nomacopan, according to a press release from Akari Therapeutics.

The use of vascular endothelial growth factor receptor tyrosine kinase inhibitors significantly increased the risk for developing all-grade and high-grade hand-foot skin reactions, according to a meta-analysis in the Journal of the American Academy of Dermatology.

Researchers found no need to exclude patients with psoriasis from ustekinumab treatment because of a negative HLA-C*06:02 genotype status.

The top stories in dermatology include research highlighting oral treatment in atopic dermatitis and suture spacing outcomes in wound closures.

Increased use of postoperative courses of oral antibiotics prescribed by dermatologists after surgical procedures may put patients at risk for adverse events, according to a study.

The New York attorney general, Letitia James, has filed a lawsuit against a Manhattan stem cell clinic and the physician running it for allegedly selling unproven treatments for lupus and other autoimmune conditions, among others.

Patients with atopic dermatitis who received baricitinib 4 mg plus a topical corticosteroid achieved 50% improvement in the Eczema Area and Severity Index score at week 16 at a significantly higher rate than patients who received placebo plus a topical corticosteroid, according to a study.

CHICAGO — Although previous results from the CANTOS study have demonstrated that targeting inflammation could significantly improve cardiovascular mortality outcomes, the drug its researchers used to test their hypothesis, canakinumab, comes with its own host of issues and is “not ready for prime time,” according to Leonard H. Calabrese, DO, vice chairman of rheumatic and immunologic disease at the Cleveland Clinic.

When Scott Gottlieb, MD, announced on March 5 that he would be resigning as Commissioner of the FDA, a ripple went through the health care regulation community about the future of many of his signature initiatives, including the Medical Device Safety Action Plan, the Biosimilars Action Plan, and the Drug Competition Action Plan.